Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Daniel, Bexell"'
Autor:
Jenny Karlsson, Hiroaki Yasui, Adriana Mañas, Natalie Andersson, Karin Hansson, Kristina Aaltonen, Caroline Jansson, Geoffroy Durand, Naveen Ravi, Michele Ferro, Minjun Yang, Subhayan Chattopadhyay, Kajsa Paulsson, Diana Spierings, Floris Foijer, Anders Valind, Daniel Bexell, David Gisselsson
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Neuroblastoma (NB) is one of the most lethal childhood cancers due to its propensity to become treatment resistant. By spatial mapping of subclone geographies before and after chemotherapy across 89 tumor regions from 12 NBs, we find that de
Externí odkaz:
https://doaj.org/article/fe608167f7ff46d5b574d7aead9ed289
Autor:
Anders Valind, Bronte Manouk Verhoeven, Jens Enoksson, Jenny Karlsson, Gustav Christensson, Adriana Mañas, Kristina Aaltonen, Caroline Jansson, Daniel Bexell, Ninib Baryawno, David Gisselsson, Catharina Hagerling
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTDespite aggressive treatment, the 5-year event-free survival rate for children with high-risk neuroblastoma is
Externí odkaz:
https://doaj.org/article/b026693053e149a8a14c87e0554ab387
Autor:
Frida Björk Gunnarsdottir, Oscar Briem, Aida Yifter Lindgren, Eva Källberg, Cajsa Andersen, Robert Grenthe, Cassandra Rosenqvist, Camilla Rydberg Millrud, Mika Wallgren, Hannah Viklund, Daniel Bexell, Martin E. Johansson, Ingrid Hedenfalk, Catharina Hagerling, Karin Leandersson
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
CD169+ resident macrophages in lymph nodes of breast cancer patients are for unknown reasons associated with a beneficial prognosis. This contrasts CD169+ macrophages present in primary breast tumors (CD169+ TAMs), that correlate with a worse prognos
Externí odkaz:
https://doaj.org/article/5e1ab31a177f477fbfdcc47e2a9ad13f
Autor:
Kristina Aaltonen, Katarzyna Radke, Aleksandra Adamska, Alexandra Seger, Adriana Mañas, Daniel Bexell
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
Neuroblastoma is a childhood cancer derived from the sympathetic nervous system. High-risk neuroblastoma patients have a poor overall survival and account for ~15% of childhood cancer deaths. There is thus a need for clinically relevant and authentic
Externí odkaz:
https://doaj.org/article/a84a512f5e3641ab9c57460d1a2c0b39
Publikováno v:
Stem Cell Research & Therapy, Vol 12, Iss 1, Pp 1-11 (2021)
Abstract Background Graft-contaminating tumor cells correlate with inferior outcome in high-risk neuroblastoma patients undergoing hematopoietic stem cell transplantation and can contribute to relapse. Motivated by the potential therapeutic benefit o
Externí odkaz:
https://doaj.org/article/eec214985ff94674886cc9e4843341b6
Autor:
Elin Almstedt, Ramy Elgendy, Neda Hekmati, Emil Rosén, Caroline Wärn, Thale Kristin Olsen, Cecilia Dyberg, Milena Doroszko, Ida Larsson, Anders Sundström, Marie Arsenian Henriksson, Sven Påhlman, Daniel Bexell, Michael Vanlandewijck, Per Kogner, Rebecka Jörnsten, Cecilia Krona, Sven Nelander
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
We lack effective treatment for half of children with high-risk neuroblastoma. Here, the authors introduce an algorithm that can predict the effect of interventions on gene expression signatures associated with high disease processes and risk, and id
Externí odkaz:
https://doaj.org/article/9eefbf3ff5bb4e6b9e9c8aacbd9a935c
Autor:
Katarzyna Radke, Karin Hansson, Jonas Sjölund, Magdalena Wolska, Jenny Karlsson, Javanshir Esfandyari, Kristian Pietras, Kristina Aaltonen, David Gisselsson, Daniel Bexell
Publikováno v:
Translational Oncology, Vol 14, Iss 8, Pp 101149- (2021)
High-risk neuroblastoma has a poor prognosis despite intense treatment, demonstrating the need for new therapeutic strategies. Here we evaluated the effects of rigosertib (ON-01910.Na) in preclinical models of high-risk neuroblastoma. Among several h
Externí odkaz:
https://doaj.org/article/6744e2c17bf2479da962240e572b1b78
Autor:
Sofie Mohlin, Karin Hansson, Katarzyna Radke, Sonia Martinez, Carmen Blanco‐Apiricio, Cristian Garcia‐Ruiz, Charlotte Welinder, Javanshir Esfandyari, Michael O'Neill, Joaquin Pastor, Kristoffer von Stedingk, Daniel Bexell
Publikováno v:
EMBO Molecular Medicine, Vol 11, Iss 8, Pp 1-17 (2019)
Abstract The PI3K pathway is a major driver of cancer progression. However, clinical resistance to PI3K inhibition is common. IBL‐302 is a novel highly specific triple PIM, PI3K, and mTOR inhibitor. Screening IBL‐302 in over 700 cell lines repres
Externí odkaz:
https://doaj.org/article/940f73d202764e8eb9fccad18ef1fd8e
Autor:
María Victoria Ruiz-Pérez, Lourdes Sainero-Alcolado, Ganna Oliynyk, Isabell Matuschek, Nicola Balboni, S.J. Kumari A. Ubhayasekera, Marteinn Thor Snaebjornsson, Kamil Makowski, Kristina Aaltonen, Daniel Bexell, Dolors Serra, Roland Nilsson, Jonas Bergquist, Almut Schulze, Marie Arsenian-Henriksson
Publikováno v:
iScience, Vol 24, Iss 2, Pp 102128- (2021)
Summary: Many metabolic pathways, including lipid metabolism, are rewired in tumors to support energy and biomass production and to allow adaptation to stressful environments. Neuroblastoma is the second deadliest solid tumor in children. Genetic abe
Externí odkaz:
https://doaj.org/article/fdcde282d39e41aa9c4af63f5a3e2e3b
Autor:
Daniel Bexell, Sven Påhlman, David Gisselsson, Tommy Martinsson, Jan Koster, Jenny Karlsson, Rosa Noguera, Ana P. Berbegall, Javanshir Esfandyari, Siv Beckman, Anna Börjesson, Torbjörn Backman, Ingrid Øra, Karin Hansson, Jakob Willforss, Fredrik Levander, Håkan Axelson, David Lindgren, Angela Martinez-Monleon, Susanne Fransson, Kristoffer von Stedingk, Noémie Braekeveldt
Supplementary Figure S2. Related to Figure 4. Intratumor heterogeneity is less prominent than intertumor heterogeneity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4018df4322af6c9a89af7822237d8445
https://doi.org/10.1158/0008-5472.22420524.v1
https://doi.org/10.1158/0008-5472.22420524.v1
